While the potential antiarrhythmic mechanisms of SGLT2 inhibitors11, 24, 25 should theoretically result in a reduction of both supraventricular and ventricular arrhythmias, the bulk of the evidence from RCTs suggests that SGLT2 inhibitors do not affect ventricular arrhythmias or sudden cardiac death.26, 27. Here, SLC5A2 is linked to Ventricular arrhythmia.